• Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2015  |  Volume : 1  |  Issue : 1  |  Page : 6-10

MicroRNAs are Related to Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Resistance in Patients with Diffuse Large B-cell Lymphoma


1 Department of Internal Medicine, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China
2 Department of Pathology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China
3 Administration Office, Henan Institute of Cancer Research, Zhengzhou, Henan, China

Correspondence Address:
Dr. Yanyan Liu
Department of Internal Medicine, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, 127 Dongming Road, Zhengzhou 450008, Henan
China
Login to access the Email id

Source of Support: The study was supported by the Natural Science Foundation of China (81071938 and 81470365),, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Aim: Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment failure is a rigorous problem in patients with diffuse large B-cell lymphoma (DLBCL), which usually predicts poor survival. The study explored the association of microRNAs with R-CHOP resistance in order to find reliable predictive factors and novel therapeutic targets. Methods: Forty-five newly diagnosed cases with DLBCL were administered with R-CHOP regimen. Thirty-three of them were divided into the sensitive group and 12 of them into the resistant group based on their response to the treatment. Both microRNAs and gene expression profilings were examined with microarray in these patients. Results: Six microRNAs were found to have significant difference between R-CHOP sensitive and resistant groups, including microRNA-9, microRNA-146a, microRNA-363, microRNA-488, microRNA-548d-3p, and microRNA-219-1-3p (P < 0.05 and absolute value of ΔΔCt > 1). Multivariate analysis showed that both microRNA-146a and microRNA-548d-3p were inversely correlated with resistance while microRNA-363 and microRNA-219-1-3p were directly correlated with resistance. Although both molecular subtypes based on cellular origin (Pearson correlation = 0.368, P = 0.023) and multiple extranodal involvement (Pearson correlation = 0.352, P = 0.030) manifested the association with R-CHOP resistance, these specific microRNAs remained independent predictors of clinical outcome in multivariate analysis. In addition, microRNA-146a was proved to have linkages with multiple extranodal involvements. Molecular subtypes based on a cellular origin were not verified to correlate with specific microRNAs. These specific microRNAs could predict resistance in 92.1% of patients in the present study. Conclusion: The expression of specific microRNAs may serve as useful biomarker for prediction of response to R-CHOP therapy in patients with DLBCL.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2541    
    Printed91    
    Emailed0    
    PDF Downloaded299    
    Comments [Add]    

Recommend this journal